Mark Lackner's Insider Trades & SAST Disclosures
Mark Lackner's most recent trade in Zentalis Pharmaceuticals Inc was a trade of 335,907 Common Stock done . Disclosure was reported to the exchange on Feb. 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark Lackner.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zentalis Pharmaceuticals Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 335,907 | 527,224 | - | 0 | Common Stock | |
| Zentalis Pharmaceuticals Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 124,714 | 124,714 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Mark Lackner | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.71 per share. | 03 Feb 2025 | 14,368 | 512,856 | - | 1.7 | 24,591 | Common Stock |
| Zentalis Pharmaceuticals Inc | Mark Lackner | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 3.12 per share. | 02 Jan 2025 | 4,411 | 191,317 | - | 3.1 | 13,762 | Common Stock |
| Zentalis Pharmaceuticals Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 141,000 | 141,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 141,000 | 197,313 | - | 0 | Common Stock | |
| Zentalis Pharmaceuticals Inc | Mark Lackner | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.54 per share. | 01 Feb 2024 | 1,585 | 195,728 | - | 11.5 | 18,291 | Common Stock |
| Zentalis Pharmaceuticals Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Mark Lackner | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 40,000 | 56,313 | - | 0 | Common Stock | |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 1,104 | 33,610 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 08 Feb 2021 | 1,104 | 0 (0%) | 0% | 21.0 | 23,234 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 08 Feb 2021 | 1,104 | 1,104 (0%) | 0% | 7.0 | 7,706 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 596 | 33,014 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 08 Feb 2021 | 596 | 0 (0%) | 0% | 21 | 12,516 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 08 Feb 2021 | 596 | 596 (0%) | 0% | 7.0 | 4,160 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 300 | 34,714 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 08 Feb 2021 | 300 | 300 (0%) | 0% | 7.0 | 2,094 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 08 Feb 2021 | 200 | 0 (0%) | 0% | 21 | 4,200 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 21.02 per share. | 08 Feb 2021 | 100 | 200 (0%) | 0% | 21.0 | 2,102 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 26 Jan 2021 | 1,701 | 800 (0%) | 0% | 18.3 | 31,124 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 26 Jan 2021 | 1,123 | 2,501 (0%) | 0% | 7.0 | 7,839 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 1,123 | 35,014 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 18.79 per share. | 26 Jan 2021 | 800 | 0 (0%) | 0% | 18.8 | 15,034 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2021 | 377 | 61,760 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.62 per share. | 26 Jan 2021 | 377 | 1,378 (0%) | 0% | 4.6 | 1,742 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 14.93 per share. | 16 Jun 2020 | 6,750 | 0 (0%) | 0% | 14.9 | 100,761 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2020 | 3,887 | 62,510 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.62 per share. | 16 Jun 2020 | 3,887 | 3,887 (0%) | 0% | 4.6 | 17,958 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 16 Jun 2020 | 2,863 | 6,750 (0%) | 0% | 7.0 | 19,984 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2020 | 2,863 | 36,137 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.62 per share. | 16 Jun 2020 | 373 | 373 (0%) | 0% | 4.6 | 1,723 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 19.91 per share. | 16 Jun 2020 | 373 | 0 (0%) | 0% | 19.9 | 7,428 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2020 | 373 | 62,137 | - | - | Stock Option (right to buy) | |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 8.55 per share. | 02 Jun 2020 | 408 | 437 (0%) | 0% | 8.5 | 3,487 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 9.73 per share. | 02 Jun 2020 | 333 | 104 (0%) | 0% | 9.7 | 3,241 | Common Stock |
| Ideaya Biosciences Inc | Mark Lackner | SVP, Head of Biology | Sale of securities on an exchange or to another person at price $ 10.11 per share. | 02 Jun 2020 | 104 | 0 (0%) | 0% | 10.1 | 1,051 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges